Pharmi에볼루션 바카라 사이트 accelerates CDMO expansion through growth of 에볼루션 바카라 사이트s handled by human 에볼루션 바카라 사이트 management business

[by Kang, In Hyo] Pharmi에볼루션 바카라 사이트 announced on May 27 that it has completed the expansion of the scope of ‘에볼루션 바카라 사이트s handled by human 에볼루션 바카라 사이트 management business,’ with the aim to expand its contract development and manufacturing (CDMO) capabilities for 에볼루션 바카라 사이트 therapy.

With the inclusion of additional 에볼루션 바카라 사이트 types, Pharmi에볼루션 바카라 사이트 is now equipped to manage a total of seven 에볼루션 바카라 사이트 types, including bone marrow-derived mononuclear 에볼루션 바카라 사이트s, as well as autologous and allogeneic mesenchymal stem 에볼루션 바카라 사이트s (MSCs) derived from bone marrow, adipose tissue, and umbilical cord sources. This development has notably enhanced the company’s capacity for 에볼루션 바카라 사이트 manufacturing and supply. Pharmi에볼루션 바카라 사이트 emphasized that this advancement lays a foundational framework for full-scale implementation of its CDMO operations, specifically aimed at supporting regenerative medicine institutions.

Pharmi에볼루션 바카라 사이트 stated that, in addition to 에볼루션 바카라 사이트 manufacturing and supply, it also offers contract testing services like sterility testing, mycoplasma contamination testing, and exogenous virus detection. Through the establishment of a comprehensive quality management system, the company has secured differentiated competitiveness as a CDMO partner in the field of 에볼루션 바카라 사이트 therapy.

According to Pharmi에볼루션 바카라 사이트, the company has over two decades of experience in the production and quality management of stem 에볼루션 바카라 사이트 therapies. Pharmi에볼루션 바카라 사이트 is equipped with advanced GMP-compliant manufacturing facilities, a robust production infrastructure grounded in human 에볼루션 바카라 사이트 management, highly skilled professional personnel, and a well-established system for testing and evaluation.

Leveraging these capabilities, Pharmi에볼루션 바카라 사이트 is positioning itself as a specialized CDMO organization that covers the entire development cycle, from early-stage R&D to clinical trials and commercialization. The company stated that it intends to further reinforce its role as a strategic partner in the Korean and international advanced regenerative medicine industry, grounded in its advanced manufacturing system and quality management capabilities.

“We intend to provide comprehensive support to advanced regenerative medicine institutions, encompassing clinical research, 에볼루션 바카라 사이트 therapy manufacturing process development, establishment of quality management systems, and therapeutic consulting,” a Pharmi에볼루션 바카라 사이트 official stated. “We will actively leverage our specialized mesenchymal stem 에볼루션 바카라 사이트 culture medium, ‘PharmiSTEM hMSC Media,’ to spearhead the rapidly growing advanced regenerative medicine market.”